Pilot study demonstrates improved stability and regenerative potential of ExoFiller in facial aesthetic patients, suggesting a durable autologous alternative for tissue augmentation.
Key Points
To evaluate the physicochemical stability, in vitro bioactivity, and clinical performance of a thermally reconstructed PRP-based biofiller (ExoFiller) compared to conventional PRP-Gel.
ExoFiller was prepared by mechanical activation, concentration, filtration, and thermal restructuring of autologous platelet-rich plasma.
In vitro tests assessed swelling behavior, degradation rates, cytokine expression via microarray, and cytocompatibility in human dermal fibroblasts.
A pilot clinical evaluation was conducted in 20 patients (aged 20 to 65 years) presenting with facial volume loss, scarring, or aesthetic rejuvenation demands.
ExoFiller demonstrated enhanced swelling capacity, slower degradation kinetics, and higher concentrations of regenerative mediators compared with conventional PRP-Gel.
In vitro testing confirmed favorable human dermal fibroblast viability and biocompatibility.
Preliminary clinical treatment achieved noticeable improvements in facial contour, volume restoration, and skin quality without adverse effects.